Enterococci and streptococci

International Journal of Antimicrobial Agents

Volumn 29, Issue SUPPL. 3, 2007, Pages

  Amyes, Sebastian G B ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Enterococcus; Epidemiology; Mechanisms; Resistance; Streptococcus

Indexed keywords

MACROLIDE; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SENSITIVITY; ENTEROCOCCAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TREATMENT FAILURE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 34447558223     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(07)72177-5     Document Type: Article

References (63)

1. Mohamed J., Huang W., Nallapareddy S., Teng F., and Murray B. Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infect Immun 72 (2004) 3658-3663
2. Creti R., Imperi M., Bertuccini L., et al. Survey for virulence determinants among Enterococcus faecalis isolated from different sources. J Med Microbiol 53 (2004) 13-20
3. Raad I., Hanna H., Boktour M., et al. Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrob Agents Chemother 49 (2005) 5046-5050
4. Evers S., Quintiliani Jr. R., and Courvalin P. Genetics of glycopeptide resistance in enterococci. Microb Drug Resist 2 (1996) 219-223
5. Gautom R., Stewart B., Coyle M., Plorde J., Schoenknecht F., and Fritsche T. Pulsed field gel electrophoretic analysis of vancomycin resistant enterococci (VREs) recovered from Seattle hospitals. Am J Clin Pathol 104 (1995) 223
6. Cormican M., Erwin M., and Jones R. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States. Diagn Microbiol Infect Dis 29 (1997) 241-248
7. Manson J., Smith J., and Cook G. Persistence of vancomycin-resistant enterococci in New Zealand broilers after discontinuation of avoparcin use. Appl Environ Microbiol 70 (2004) 5764-5768
8. Casewell M., Friis C., Marco E., McMullin P., and Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother 52 (2003) 159-161
9. Health Protection Agency. Mandatory Surveillance of Healthcare Associated Infection Report, 2006. HPA; 2006. http://www.hpa.org.uk/infections/topics_az/hai/mandatory_report_2006.htm [accessed 30 January 2007].
10. Van der Auwera P., Pensart N., Korten V., Murray B., and Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis 173 (1996) 1129-1136
11. Salgado C., Giannetta E., and Farr B. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile. Infect Control Hosp Epidemiol 25 (2004) 413-417
12. Leclercq R., Derlot E., Duval J., and Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319 (1988) 157-161
13. Arthur M., and Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37 (1993) 1563-1571
14. Marshall C., Lessard I., Park I., and Wright G. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. Antimicrob Agents Chemother 42 (1998) 2215-2220
15. Evers S., and Courvalin P. Regulation of vanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J Bacteriol 178 (1996) 1302-1309
16. Lefort A., Baptista M., Fantin B., et al. Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis. Antimicrob Agents Chemother 43 (1999) 476-482
17. Obaro S. The new pneumococcal vaccine. Clin Microbiol Infect 8 (2002) 623-633
18. Bogaert D., De Groot R., and Hermans P. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 (2004) 144-154
19. Dobay O., Rozgonyi F., and Amyes S. Virulence factors, antibiotic resistance mechanisms and the prevalence of resistance worldwide in Streptococcus pneumoniae. Rev Med Microbiol 15 (2004) 27-39
20. Linares J., Alonso T., Perez J., et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 30 (1992) 279-288
21. Sutcliffe J., Tait-Kamradt A., and Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 40 (1996) 1817-1824
22. Diekema D., BootsMiller B., Vaughn T., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
23. Bouchillon S., Hoban D., Johnson B., et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 51 (2005) 291-295
24. Johnson A., Tysall L., Stockdale M., et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 21 (2002) 751-754
25. Ruggero K., Schroeder L., Schreckenberger P., Mankin A., and Quinn J. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 47 (2003) 511-513
26. Marshall S., Donskey C., Hutton-Thomas R., Salata R., and Rice L. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 46 (2002) 3334-3336
27. Seedat J., Zick G., Klare I., Konstabel C., Weiler N., and Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 50 (2006) 4217-4219
28. Pankey G., and Sabath L. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 38 (2004) 864-870
29. Bradford P., Weaver-Sands D., and Petersen P. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41 Suppl. 5 (2005) S315-SS32
30. Sader H., Jones R., Stilwell M., Dowzicky M., and Fritsche T. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 52 (2005) 181-186
31. Betriu C., Culebras E., Rodriguez-Avial I., Gomez M., Sanchez B., and Picazo J. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 48 (2004) 323-325
32. Dobay O., Rozgonyi F., Hajdu E., Nagy E., Knausz M., and Amyes S. Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary. J Antimicrob Chemother 51 (2003) 887-893
33. Fritsche T., Sader H., Stilwell M., Dowzicky M., and Jones R. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52 (2005) 187-193
34. Moore P., and Lindsay J. Molecular characterisation of the dominant UK methicillin-resistant Staphylococcus aureus strains, EMRSA-15 and EMRSA-16. J Med Microbiol 51 (2002) 516-521
35. Plant W., Winney R., Brown A., et al. Vancomycin-resistant enterococci: epidemiology and control of an epidemic in a renal unit. In Program and Abstracts of The Renal Association. 1999. London, UK. Kidney Int 55 (1999) 2109-2110
36. Brown A., Amyes S., Paton R., et al. Epidemiology and control of vancomycin-resistant enterococci (VRE) in a renal unit. J Hosp Infect 40 (1998) 115-124
37. Nelson R., McGregor K., Brown A., Amyes S., and Young H. Isolation and characterization of glycopeptide-resistant enterococci from hospitalized patients over a 30-month period. J Clin Microbiol 38 (2000) 2112-2116
38. Brown A., Townsley A., and Amyes S. Diversity of Tn1546 elements in clinical isolates of glycopeptide-resistant enterococci from Scottish hospitals. Antimicrob Agents Chemother 45 (2001) 1309-1311
39. Lai M., and Kirsch D. Induction signals for vancomycin resistance encoded by the vanA gene cluster in Enterococcus faecium. Antimicrob Agents Chemother 40 (1996) 1645-1648
40. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 7 (2001) 229-236
41. Bartley P., Schooneveldt J., Looke D., Morton A., Johnson D., and Nimmo G. The relationship of a clonal outbreak of Enterococcus faecium vanA to methicillin-resistant Staphylococcus aureus incidence in an Australian hospital. J Hosp Infect 48 (2001) 43-54
42. Oprea S., Zaidi N., Donabedian S., Balasubramaniam M., Hershberger E., and Zervos M. Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother 53 (2004) 626-630
43. Noble W., Virani Z., and Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72 (1992) 195-198
44. Chang S., Sievert D., Hageman J., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348 (2003) 1342-1347
45. Tenover F., Weigel L., Appelbaum P., et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48 (2004) 275-280
46. Whitener C., Park S., Browne F., et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 38 (2004) 1049-1055
47. Courvalin P. Genetics of glycopeptide resistance in gram-positive pathogens. Int J Med Microbiol 294 (2005) 479-486
48. Palmieri C., Vecchi M., Littauer P., Sundsfjord A., Varaldo P., and Facinelli B. Clonal spread of macrolide-and tetracycline-resistant [erm(A) tet(O)] emm77 Streptococcus pyogenes isolates in Italy and Norway. Antimicrob Agents Chemother 50 (2006) 4229-4230
49. Ardanuy C., Tubau F., Linares J., Dominguez M., Pallares R., and Martin R. Distribution of subclasses mefA and mefE of the mefA gene among clinical isolates of macrolide-resistant (M-phenotype) Streptococcus pneumoniae, viridans group streptococci, and Streptococcus pyogenes. Antimicrob Agents Chemother 49 (2005) 827-829
50. Brenciani A., Ojo K., Monachetti A., et al. Distribution and molecular analysis of mef (A)-containing elements in tetracycline-susceptible and -resistant Streptococcus pyogenes clinical isolates with efflux-mediated erythromycin resistance. J Antimicrob Chemother 54 (2004) 991-998
51. Bingen E., Bidet P., Mihaila-Amrouche L., et al. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother 48 (2004) 3559-3562
52. Kataja J., Huovinen P., Efstratiou A., Perez-Trallero E., and Seppala H. Clonal relationships among isolates of erythromycin-resistant Streptococcus pyogenes of different geographical origin. Eur J Clin Microbiol Infect Dis 21 (2002) 589-595
53. Seppala H., Haanpera M., Al-Juhaish M., Jarvinen H., Jalava J., and Huovinen P. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J Antimicrob Chemother 52 (2003) 636-644
54. Cerda Zolezzi P., Laplana L., Calvo C., Cepero P., Erazo M., and Gomez-Lus R. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 48 (2004) 3462-3467
55. Munoz R., Coffey T., Daniels M., et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 164 (1991) 302-306
56. McGee L., McDougal L., Zhou J., et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 39 (2001) 2565-2571
57. Coffey T., Dowson C., Daniels M., et al. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol 5 (1991) 2255-2260
58. McCullers J., English B., and Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 181 (2000) 369-373
59. Barnes D., Whittier S., Gilligan P., Soares S., Tomasz A., and Henderson F. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain in vivo. J Infect Dis 171 (1995) 890-896
60. Coffey T., Enright M., Daniels M., et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 27 (1998) 73-83
61. Linden P. Treatment options for vancomycin-resistant enterococcal infections. Drugs 62 (2002) 425-441
62. Auckland C., Teare L., Cooke F., et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50 (2002) 743-746
63. Lewis II J., Owens A., Cadena J., Sabol K., Patterson J., and Jorgensen J. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49 (2005) 1664-1665